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doi:10.1016/j.jmii.2010.04.001Accurately differentiating tuberculous pleurisy from lung cancer is important for disease
management but difficult using conventional laboratory methods. This study assessed the
value of adenosine deaminase (ADA) and interferon gamma (IFN-g) for differentiating the
two conditions in a region of Taiwan with a high prevalence of tuberculosis. The study popu-
lation comprised patients with lymphocytic exudative pleural effusions: tuberculous (nZ 24)
and malignant (nZ 42). Mean levels of ADA and IFN-g in pleural fluid, measured with
commercial standardized kits, were significantly higher for tuberculous than for malignant
pleurisy (p< 0.001 for both). For differentiating the two effusions, results for ADA versus
IFN-g were: sensitivity, 70.8% versus 91.7%; specificity, 95.2% versus 97.6%; positive predic-
tive value, 89.5% versus 96.7%; and negative predictive value, 85.1% versus 95.3%. IFN-g
allows precise diagnosis of pleural tuberculosis, but ADA is easier to use, has a low cost,
and results are quickly available. Our study confirms previous studies and extends the useful-
ness of these diagnostic methods to a wider group of clinical laboratories by showing theicrobiology, Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital,
iwan.
v.tw (T.-S. Huang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
ADA and IFN-g for diagnosing tuberculous pleurisy 89reliability of standardized relatively inexpensive commercial kits. We recommend that initial
ADA screening be used in conjunction with IFN-g measurements for differential diagnosis of
tuberculous pleurisy.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
There are many causes of pleural effusion, and an effusion
caused by tuberculous pleurisy may be difficult to distin-
guish from one caused by some form of cancer. A rapid
precise diagnosis is important as the prognosis and therapy
for these two diseases are markedly different. Unlike some
other studies, we restricted our analysis to these two
groups to mimic the common clinical situation. A definitive
diagnosis of tuberculous pleural effusion can be difficult
because of nonspecific clinical presentation and the rela-
tively poor efficiency of traditional diagnostic methods. In
clinical practice, the predictive value is an important
measure of diagnostic validity. The positive predictive
value (PPV) is the probability of the presence of a disease,
given a positive test result. Likewise, the negative predic-
tive value (NPV) is the probability of absence of a disease,
given a negative test result.
Detection of Mycobacterium tuberculosis using primary
culture or the polymerase chain reaction usually allows
definitive diagnosis, although the positive rate of pleural
fluid culture for M tuberculosis is low in tuberculous
pleurisy.1,2 Because of the long culture period, clinical and
therapeutic decisions often have to be made before
culture results become available. The sensitivities of
pleural fluid culture, pleural biopsy culture, and histolog-
ical examination of a pleural biopsy sample, are reported
to be on the order of 23%, 55%, and 63%, respectively.3
Another method, acid-fast staining of pleural effusion
fluid, has the advantage of being rapid and inexpensive but
lacks sensitivity and often produces negative results even
in patients with a confirmed diagnosis of tuberculous
pleurisy.
The inefficiency of conventional laboratory methods
has resulted in the development and evaluation of alter-
native diagnostic strategies. In recent years, both aden-
osine deaminase (ADA) activity and interferon gamma
(IFN-g) concentrations have been reported as useful
diagnostic markers of tuberculous pleurisy.4e12 However,
one limitation of predictive values is their dependence on
disease prevalence.13 If the sensitivity and specificity of
a diagnostic test were constant, then the PPV would
increase with disease prevalence, whereas the NPV would
decrease with disease prevalence. Thus, the prevalence
of tuberculosis (TB) has a strong impact on the predictive
values of clinical diagnostic tests. The value of ADA in the
diagnosis of tuberculous pleurisy in a country with a high
burden of TB, such as Taiwan, has not been reported
previously.
A previous prospective study showed that using ADA in
combination with the lymphocyte/neutrophil (L:N) ratio
increased the specificity of tuberculous pleurisy diagnosis.4In this report, the study population was restricted to one of
the most diagnostically challenging categories of pleural
effusions, namely, patients with lymphocyte-predominant
exudative pleural effusions. The goal of the present study
was to evaluate the diagnostic value of using rapid
commercial ADA and IFN-g quantification kits for differen-
tiating between tuberculous pleurisy and malignant pleurisy
in patientswith lymphocytic exudative pleural effusions. Use
of such kitswouldmake these tests available to awider range
of clinical laboratories. We evaluated the sensitivity, speci-
ficity, and PPVs and NPVs of the ADA and IFN-g tests in this
setting and provided recommendations for routine clinical
practice.Materials and methods
Patients
This study was approved by the Institutional Review Board
of Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan. Informed consent was obtained from patients who
participated in the study. Pleural effusions were collected
from consecutive patients who were admitted to Kaohsiung
Veterans General Hospital between July 2006 and January
2007. Samples from consecutive patients (nZ 177) with
lymphocytic exudative pleural effusions were screened for
inclusion in this study. Patients with exudative effusion and
lymphocyte counts less than 50% were excluded from
further analyses (nZ 54). Among the remaining 123
patients, patients with TB and malignancies were eligible
for further analysis. Clinical signs and symptoms, demo-
graphic data, and radiologic results were recorded. Results
of ADA and IFN-g tests were blinded to the physicians to
avoid bias in determination of patient clinical diagnosis.
Diagnostic criteria
Patients were included in the study if they had exudative
pleural effusions with lymphocyte counts of 50% or more.
Pleural effusions were classified as exudates if the pleural
fluid-to-serum ratio of total protein was 0.5 or more, the
pleural fluid level of absolute lactic dehydrogenase (LDH)
was 200 IU/L or more, or the pleural LDH fluid-to-serum
ratio was 0.6 or more.1 A diagnosis of pleural TB was made
if patients had one of the following clinical manifestations
suggestive of TB: M tuberculosis isolated from pleural
fluid or pleural tissue, granulomas in the pleural tissue
that stained positive for acid-fast bacilli (AFB), or granu-
lomas in the pleural tissue that did not stain positive for
AFB but did show a response following antituberculous
treatment. The diagnosis of malignant pleurisy was made
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ical study, or if histopathology examination found malig-
nant cells in a biopsy sample of pleural tissue. Causes of
pleural effusion were determined using established clin-
ical criteria.1,14,15
Specimen collection and processing
At least 40 mL of pleural fluid was collected from each
patient during thoracentesis using a sterile syringe. Aliquots
of each sample were submitted for AFB staining; bacterio-
logical examination; cytological examination; and
measurements of protein, albumin, total bilirubin, LDH,
and glucose concentrations. A separate aliquot was
centrifuged at 2,000 revolutions per minute for 10 minutes
and the supernatant was frozen at 80C for further anal-
yses within 2 months.
ADA activity
ADA activity was determined at 37C using a commercial kit
(Adenosine Deaminase Assay Kit; Diazyme Laboratories, San
Diego, CA, USA) based on the Berthelot reaction according
to the method described by Giusti and Galanti.16 Briefly,
a colored indophenol complex formed from ammonia
liberated from adenosine was quantified spectrophoto-
metrically. One unit of ADA was defined as the amount of
enzyme required to release 1 mmol of ammonia/min from
adenosine under standard assay conditions. Results are
expressed in international units of enzyme activity in
a standard volume of pleural fluid.
IFN-g levels in pleural fluid
IFN-g levels were measured using a commercial Cytometric
Bead Array (CBA) kit (Becton Dickinson, San Diego, CA, USA)
according to the manufacturer’s instructions. Briefly, dyed
microparticles with a maximal emission wavelength of
approximately 650 nm fluorescence-3 (FL-3) were coated
with antibodies specific to human IFN-g (Ab-bead reagent).
IFN- g was detected directly, using the antibody fused with
phycoerythrin (PE), which emits fluorescence at 585 nm
(FL-2). The intensity of FL-2 was proportional to the cyto-
kine concentration in the sample, and the results were
derived from a calibration curve. For each pleural fluid
sample and cytokine standard mixture, 50 mL of sample or
standard was added to a mixture of 50 mL each of capture
Ab-bead reagent and detector Ab-PE antibody reagent. The
mixture (150 mL) was incubated for 2 hours at room
temperature to form sandwich complexes and washed to
remove unbound detector Ab-PE antibody before data
acquisition using flow cytometry.
Two-color cytometric analysis used a FACSCalibur flow
cytometer (Becton Dickinson Immunocytometry Systems,
San Jose, CA, USA). Data were analyzed using CBA soft-
ware. Dot-plot forward versus side scatter was used to
distinguish between particles and to detect cytokine
particles. Human IFN-g concentrations were determined
from standard curves (cytokine calibrator concentration vs.
FL-2 median fluorescence intensity) using a four-parameter
logistic curve-fitting model.Culture and identification
Mycobacterium culture was performed by inoculation of
individual specimen samples into Lowenstein-Jensen
medium and into one mycobacteria growth indicator tube
and tested using a mycobacteria growth indicator tube 960
instrument (Becton Dickinson Diagnostic Systems, Sparks,
MD, USA). Positive growth was identified using the BDPro-
beTEC ET CTB assay (Becton DickinsonMicrobiology Systems,
Maryland, MD, USA).
Statistical analyses
Results are given as the mean standard deviation for
normally distributed, continuous variables, or as the
median (interquartile range) for non-normally distributed
variables. Results for categorical variables are given as
percentages (%). Normally distributed continuous variables
were compared using an independent, two-sample t test. A
Mann-Whitney U test was used for non-normally distributed
variables. Categorical variables were compared by a c2
test. The optimal cutoff values for ADA and IFN-g in the
diagnosis of tuberculous pleurisy were determined using
receiver operator characteristic curves. The McNemar test
was used to test for significant differences between two
diagnoses of tuberculous pleurisy. All statistical assess-
ments were two sided, and analyses used SPSS 15.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). Significance
was accepted for p values less than 0.05.
Results
From an initial population of 123 patients with lymphocytic
exudative pleural effusions, samples from 24 patients
(36.4%) with tuberculous pleurisy and 42 patients (63.6%)
with malignant pleural effusions were subjected to further
analyses. Baseline demographic characteristics and pleural
effusion biochemistry findings are shown in Table 1.
Patients with malignant pleural effusions were significantly
older than those with tuberculous pleural effusions
(70.4 12.50 years vs. 61.0 18.96 years, pZ 0.037).
There were no statistically significant differences between
these two groups for effusion concentrations of protein,
glucose, or LDH.
Importantly, as shown in Table 2, ADA levels and IFN-g
concentrations were significantly higher in patients with
tuberculous pleurisy than in patients withmalignant pleurisy
(p< 0.001 for both). Among patients with tuberculous
pleurisy, IFN-g concentrations were significantly higher in
patients with positive cultures than in patients with negative
cultures (929 pg/mL vs. 280 pg/mL, pZ 0.012). There was
no significant difference for ADA levels from patients who
had positive or negative cultures. In addition, there was
a significant difference in IFN-g between culture-negative
TB and malignant effusions (279 pg/mL vs. 3.49 pg/mL,
p< 0.001). No significant difference for ADA levels between
culture-negative TB and malignant effusion was found.
Figure 1 shows the receiver operator characteristic
curves for the diagnostic parameters of ADA and IFN-g. The
area under the curve for ADA was 0.76 (p< 0.001, 95%
confidence interval: 0.612e0.909), whereas the area under
Table 1 Demographics and biochemistry findings from pleural fluid for patients with tuberculous and malignant pleurisy (nZ 66)a
Variable Tuberculous pleurisy (nZ 24) Malignant pleurisy (nZ 42)
Total (nZ 24) Culture positive
(nZ 13)
Culture negative
(nZ 11)
Total (nZ 42) Lung cancer
(nZ 32)
Other malignancy
(nZ 10)
Age (yr) 61.00 18.96b 60.31 20.81 61.80 17.49 70.40 12.5b 72.06 11.50 65.10 14.67
Sex, male 18 (75.0) 8 (72.7) 10 (76.9) 28 (66.7) 23 (71.9) 5 (50.0)
Protein (g/dL) 4.50 1.00 4.65 1.09 4.35 0.92 4.28 0.98 4.35 0.87 4.07 1.26
LDH (IU/L) 368 (232e653) 322 (192e653) 393 (281.5e783) 282.5 (186e551) 282.5 (186e441) 382 (213e649)
Glucose (mg/dL) 95.5 (69e130) 118 (73e155) 83 (60e115) 113 (96e128) 106 (93e141) 118.5 (100e127)
a Data are presented as mean  standard deviation, n(%) or median (interquartile range).
b Significant difference between tuberculous and malignant groups, p< 0.05.
LDHZ lactic dehydrogenase.
Table 2 Mean IFN-g and ADA levels for patients with tuberculous and malignant pleurisy (nZ 66)a
Parameter Tuberculous pleurisy (nZ 24) Malignant pleurisy (nZ 42)
Total (nZ 24) Culture positive (nZ 13) Culture negative (nZ 11) Total (nZ 42) Lung cancer (nZ 32) Other malignancy
(nZ 10)
ADA (IU/L) 42.76 (17.19e64.34)b 44.43 (39.82e63.71) 19.70 (10.06e64.97) 16.35 (12.99e21.38)b 16.35 (12.16e21.38) 17.82 (14.26e23.05)
IFN-g (pg/mL) 580.61 (174.64e1,611.39)b 929.02 (722.40e2,781.03)c 279.55 (118.37e427.98)c 3.49 (0.00e8.39)b 3.41 (0.00e8.14) 5.23 (0.00e16.07)
a Data are presented as median (interquartile range).
b Significant difference between tuberculous and malignancy groups, p< 0.05.
c Indicates significant difference between culture positive and negative in tuberculous groups, p< 0.05.
The p values are based on Mann-Whitney U tests.
ADAZ adenosine deaminase; IFN-gZ interferon gamma.
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Figure 1. Receiver operator characteristic curves for
determining optimal ADA and IFN-g cutoff values for diagnosing
tuberculous pleurisy. ADAZ adenosine deaminase; IFN-
gZ interferon gamma.
92 Y.-C. Liu et al.the curve for IFN-g was 0.96 (p< 0.001, 95% confidence
interval: 0.892e1.024). The cutoff values determined to give
the best diagnostic accuracywere 30 IU/L for ADA and 70 pg/
mL for IFN-g. The results for comparing ADA versus IFN-g
were: sensitivity, 70.8% versus 91.7%; specificity, 95.2%
versus 97.6%; PPVs, 89.5% versus 97.5%; and NPVs, 85.1%
versus 95.3% (Table 3). Based on the results of a McNemar
test, there was no significant difference between ADA and
IFN-g as diagnostic parameters (pZ 0.289).
Discussion
A prompt accurate differential diagnosis of pleural
exudates is vital for initiating treatment, particularly for
cases with TB. A definitive diagnosis of tuberculous pleurisy
is traditionally based on one or more of the following:
identification of M tuberculosis in the pleural fluid or in
a biopsy sample or from histopathological observation of
granulomas in the pleural tissue. These conventionalTable 3 Accuracy of ADA and IFN-g cutoff values for the diagn
Cutoff values TB (nZ 24) Malignancy (nZ 42) Sensitivity
ADA (IU/L)
30 17 2 70.8
<30 7 40
IFN-g (pg/mL)
70 22 1 91.7
<70 2 41
ADAZ adenosine deaminase; AUCZ area under the curve; CIZ c
predictive value; PPVZ positive predictive value; TBZ tuberculosis.methods generally have poor sensitivity and are time
consuming because the cultures require time to grow.
Although a biopsy sample of the pleura is more sensitive, it
is also more invasive, which increases the possibility of
associated morbidity and is subject to sampling error.17
Other methods, such as thoracoscopy18 or polymerase
chain reaction,11,19 may enhance diagnostic sensitivity and
specificity and may shorten the time to differential diag-
nosis. Yet, these procedures may be invasive or may be
costly in terms of required equipment and trained
personnel. Thus, these methods may not be readily avail-
able, particularly for resource-poor clinics or hospitals. An
alternative is the examination of pleural exudates for
biomarkers that can be reliable for differential diagnoses.
ADA activity is principally because of ADA produced by
monocytes20 and is indicative of a local, active, inflamma-
tory response. IFN-g, secreted by antigen-triggered CD4þ
lymphocytes, is a key lymphokine that activates macro-
phages, increasing their bactericidal activity against
M tuberculosis.21 Methods, such as measurements of ADA
activity and IFN-g levels, have proven to be sensitive and
specific for pleural TB in populations with a high prevalence
of TB.22e28
The criteria for exudates were first proposed by Light
et al.5 and have become the accepted standard for accu-
rate identification of exudative effusions, although the
marker LDH has subsequently been demonstrated to have
no role in differentiating between transudates and
exudates.29 In addition, a predominance of small lympho-
cytes in a pleural effusion is thought to indicate that the
patient most likely has cancer or tuberculous pleuritis. The
combined use of ADA activity and differential cell counts
provides a more efficient means for diagnosing tuberculous
pleurisy27 than the use of ADA levels alone.16,30
Therefore, only exudates containing more than 50%
lymphocytes were included in the present study. Previous
studies have shown that more than 90% of TB effusions
are lymphocytic, that is, with a lymphocyte count of
more than 50%.14 In our study, none of the 54 patients
who had exudative pleural effusions and lymphocyte
counts less than 50% were diagnosed as tuberculous
pleurisy.
The present study demonstrates that ADA and IFN-g
concentrations in pleural fluid are useful tools for the
differential diagnosis of tuberculous pleurisy. IFN-g was
a better diagnostic marker than ADA for tuberculous pleu-
risy, with a higher sensitivity and specificity and a PPV. A
recent meta-analysis of the diagnostic value of ADA inosis of clinical tuberculous pleurisy (nZ 66)
(%) Specificity (%) PPV (%) NPV (%) AUC (95% CI)
95.2 89.5 85.1 0.76 (0.61e0.91)
97.6 95.7 95.3 0.96 (0.89e1.02)
onfidence interval; IFN-gZ interferon gamma; NPVZ negative
ADA and IFN-g for diagnosing tuberculous pleurisy 93tuberculous pleural effusion reported sensitivities ranging
from 47.1% to 100%.6 Interestingly, better ADA diagnostic
performance was observed in studies conducted in Europe,
whereas performance was poorer in studies from East Asia
than from other regions.6 A study from Hong Kong also
showed lower ADA sensitivity for diagnosis of tuberculous
pleurisy.7 This suggests the possibility that population
ethnicity has an influence on the diagnostic value of ADA.31
Lower ADA levels among Asians may compromise its
usefulness in TB detection in this population.6
Reported ADA and IFN-g cutoff values for the diagnosis
of tuberculous pleurisy vary greatly. This discrepancy can
be attributed, in part, to the use of different methods.
With the most frequently reported colorimetric ADA assay,
described by Giusti and Galanti,16 the reported cutoff value
for ADA varies from 40 IU/L to 60 IU/L.5,27,29,30,32e34 Our
cutoff value of 30 IU/L was lower than this range, although
this may be because of the ethnicity of our study pop-
ulation. The cutoff values for IFN-g vary from 60 pg/mL to
240 pg/mL, based on an enzyme-linked immunosorbent
assay.35e37 The only report using the CBA method listed
a cutoff of 100 pg/mL.38
In the present study, two commercial kits were used to
determine ADA and IFN-g. The main advantages of these
kits are that they are standardized and can be incorpo-
rated easily into the routine workflow. In addition,
specialized equipment and personnel training are not
required. Our study using these kits not only confirms
results reported previously by others but also shows further
that similar diagnostic results can be obtained using
commercial kits. Thus, many more clinical laboratories can
expect reliable results even without sophisticated equip-
ment or highly trained personnel. More general use of
standardized test kits also can be reasonably expected to
lead to more uniform cutoff values for improved compa-
rability between laboratories and to help determine the
effect of ethnicity.
ADA has the advantage of cost effectiveness, efficiency,
noninvasiveness, and ease of use. This established marker
has proven utility in distinguishing between tuberculous
and nontuberculous respiratory disease.39e41 IFN-g
concentrations in pleural effusions were determined with
a CBA kit. When compared with conventional enzyme-
linked immunosorbent assay methods, this microparticle-
based flow cytometric immunoassay has been proven to
have comparable analytical sensitivity.38 In addition, CBA is
a suite of products that has been optimized for ease of use
and time efficiency.
In conclusion, the present study compared ADA and IFN-
g concentrations in pleural effusion fluids from patients
with lymphocyte-predominant exudative pleural effusions.
Although both markers were useful for distinguishing
between tuberculous and malignant pleurisy, results indi-
cate that the IFN-g level was a better diagnostic marker of
tuberculous pleurisy than ADA activity. When measurement
of IFN-g is not readily available because of cost or other
reasons, ADA remains useful for initial differential diag-
nosis. Should diagnostic uncertainty remain, IFN-g
measurement should be considered. However, neither ADA
nor IFN-g can replace bacterial culture, which remains
necessary for susceptibility testing to guide antituberculous
therapy.Acknowledgment
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